What's more, it is widely believed that l‐Dopa treatment stimulates D1R signaling leading to a persistent D1R hypersensitivity and contributing to the genesis of long‐term complications involving l‐Dopa including the development of l‐Dopa‐induced dyskinesia (Corvol et al. 2004; Solis et al. 2017). This evidence concerns the gene DRD1 and drug-induced dyskinesia.